ASX Announcements

European Commission grants 3 NNZ-2591 Orphan designations
Notification of investor briefing webinar
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591
Approval received for final stage of NNZ-2591 clinical trial
Quarterly report and cash flow statement for Q3 2020
Neuren requests Orphan designations for NNZ-2591 in Europe
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
Half-year Shareholder Update
Half Yearly Report and Accounts
Corporate presentation, 18 August 2020